Akari Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Samir Patel

Chief executive officer

US$9.8k

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	20.5%
Management average tenure	no data
Board average tenure	3.9yrs

Recent management updates

Recent updates

Akari Therapeutics GAAP EPS of $0.00

Sep 27

Will Akari Therapeutics (NASDAQ:AKTX) Spend Its Cash Wisely?

Sep 20

Akari Therapeutics announces positive results from pre-clinical studies of eye disease treatment

Jul 28

Akari Therapeutics GAAP EPS of $0.00

Jul 20

Patient completes course with Akari's stem cell transplant related complication treatment

Jul 07

We're Keeping An Eye On Akari Therapeutics' (NASDAQ:AKTX) Cash Burn Rate

Dec 31

Akari shares rise after FDA 'fast track' status for skin disease treatment nomacopan

Apr 28

Akari Therapeutics reports FY results

Apr 21

We Think Akari Therapeutics (NASDAQ:AKTX) Needs To Drive Business Growth Carefully

Mar 15

Akari Therapeutics' lead candidate shows encouraging preclinical action against inflammatory eye disease

Dec 03

CEO

Samir Patel (55 yo)

less than a year

Tenure

US$9,807

Compensation

Dr. Samir Rashmikant Patel, M.D. served as an Independent Director of Akari Therapeutics, plc since November 29, 2023 until May 1, 2024 and also serves as its Interim President, Chief Executive Officer and...

Board Members

Name	Position	Tenure	Compensation	Ownership
Samir Patel	Interim President	less than a year	US$9.81k	20.53% $ 5.8m
Sandip Patel	Independent Director	no data	no data	4.28% $ 1.2m
Robert Bazemore	Director	less than a year	no data	no data
James Neal	Independent Director	no data	no data	0.093% $ 26.2k
Hoyoung Huh	Chairman	no data	no data	32.73% $ 9.2m
Raymond Prudo-Chlebosz	Director	9.8yrs	US$113.00k	15.3% $ 4.3m
Michael Grissinger	Independent Director	6.8yrs	US$66.85k	0.084% $ 23.6k

3.9yrs

Average Tenure

57yo

Average Age

Experienced Board: AKTX's board of directors are considered experienced (3.9 years average tenure).

Akari Therapeutics Management

Management criteria checks 2/4

Key information

Recent management updates

Akari Therapeutics, plc Appoints Samir R. Patel as Interim President

Akari Therapeutics, Plc, Annual General Meeting, Jun 27, 2024

Melissa Bradford-Klug to Step Down as Chief Operating Officer of Akari Therapeutics, Plc

Akari Therapeutics Appoints Samir R. Patel, M.D. to Board of Directors

Akari Therapeutics, Plc Announces Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs, Effective September 1, 2023

Akari Therapeutics, plc Announces Appointment of Wendy Dicicco as Interim Chief Financial Officer

Recent updates

Akari Therapeutics, Plc announced delayed 10-Q filing

Akari Therapeutics, Plc announced that it expects to receive $3.2 million in funding

Akari Therapeutics Receives Delisting Determination Letter from Nasdaq Due to Failure to Meet the Terms of an Extension Granted by Nasdaq to Regain Compliance with the Stockholders’ Equity Requirement

Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy

Akari Therapeutics, Plc announced delayed 10-Q filing

New major risk - Share price stability

Akari Therapeutics, plc Appoints Samir R. Patel as Interim President

Akari Therapeutics, Plc, Annual General Meeting, Jun 27, 2024

Akari Therapeutics, Plc announced that it has received $0.5 million in funding

New major risk - Financial position

Melissa Bradford-Klug to Step Down as Chief Operating Officer of Akari Therapeutics, Plc

Akari Therapeutics Receives a Letter from the Listing Qualifications Staff of the Nasdaq Capital Market

New minor risk - Share price stability

New major risk - Shareholder dilution

New major risk - Market cap size

Akari Therapeutics, Plc (NasdaqCM:AKTX) entered into a definitive agreement to acquire Peak Bio, Inc. (OTCPK:PKBO).

Akari Therapeutics Appoints Samir R. Patel, M.D. to Board of Directors

Akari Therapeutics, Plc announced that it expects to receive $2 million in funding

Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Akari Therapeutics, Plc Announces Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs, Effective September 1, 2023

Akari Therapeutics, plc Grants Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation

Akari Therapeutics, plc Announces Appointment of Wendy Dicicco as Interim Chief Financial Officer

Less than half of directors are independent

Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA

Akari Therapeutics, plc Announces Updates on the Development of Long-Acting Pas-Nomacopan as A Potential Treatment for Geographic Atrophy

Akari Therapeutics, plc Announces Management Appointments

Akari Therapeutics, Plc, Annual General Meeting, Jun 30, 2023

Akari Therapeutics, Plc Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy

Akari Therapeutics Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan for Treatment of Pediatric Hsct-Tma into Pivotal Part B and Addition of A New Pipeline Program Developing Nomacopan for Hsct-Tma in Adults

Price target decreased to US$4.00

Insufficient new directors

Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of nomacopan for the Treatment of Pediatric HSCT-TMA

Akari Therapeutics Announces the Appointment of John F. Neylan, III as Executive Vice President, Chief Medical Officer

Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

Akari Therapeutics GAAP EPS of $0.00

Will Akari Therapeutics (NASDAQ:AKTX) Spend Its Cash Wisely?

Akari Therapeutics, plc Announces That It Is Prioritizing Two Pipeline Programs

Insufficient new directors

Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy

Akari Therapeutics announces positive results from pre-clinical studies of eye disease treatment

Akari Therapeutics GAAP EPS of $0.00

Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase Iii Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy

Patient completes course with Akari's stem cell transplant related complication treatment

Akari Therapeutics, Plc Appoints Melissa Bradford-Klug as Chief Operating Officer, Effective July 1, 2022

Akari Therapeutics, Plc, Annual General Meeting, Jun 30, 2022

Akari Therapeutics, Plc Presents Results from the CASCADE and CORONET Studies in COVID-19

Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA Dermatology

Akari Therapeutics, Plc Presents Positive Results from Two Preclinical Studies of Its Lead Asset, Investigational Nomacopan

Insufficient new directors

Akari Therapeutics, Plc Appoints Rachelle Jacques as President and Join its Board of Directors

Akari Therapeutics, Plc Appoints Rachelle Jacques as President and Join its Board of Directors

Akari Therapeutics, plc Announces New Data Showing That Clinical Outcomes in U.S. Army Trauma Patients Correlate with Complement Activation

Akari Therapeutics, plc Announces Advances Lung Program with Inhaled Nomacopan Focused on Early Treatment of Severe Exacerbations in Lung Diseases

Akari Therapeutics, Plc announces FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies

We're Keeping An Eye On Akari Therapeutics' (NASDAQ:AKTX) Cash Burn Rate

Akari Therapeutics, Plc Presents New Data Revealing Potential Mechanism of Action Driving Serious Exacerbations Across Lung Disorders

Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid

Akari shares rise after FDA 'fast track' status for skin disease treatment nomacopan

Akari Therapeutics reports FY results

We Think Akari Therapeutics (NASDAQ:AKTX) Needs To Drive Business Growth Carefully

Akari Therapeutics, Plc Announces a Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research for Nomacopan in Trauma

Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis

New 90-day high: US$3.88

Akari Therapeutics Adds Histamine Inhibitor Votucalis to Pipeline to Treat Neuropathic Pain and Dermatological Disease

Do Institutions Own Akari Therapeutics, Plc (NASDAQ:AKTX) Shares?

New 90-day high: US$2.05

Read This Before Selling Akari Therapeutics, Plc (NASDAQ:AKTX) Shares

New 90-day high: US$2.00

Akari Therapeutics, Plc Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and Substantially Reduces Transfusion Dependence in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)